CDXC Stock Overview
Operates as a bioscience company focusing on developing healthy aging products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ChromaDex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.49 |
| 52 Week High | US$7.97 |
| 52 Week Low | US$1.36 |
| Beta | 2.15 |
| 1 Month Change | -26.80% |
| 3 Month Change | 51.24% |
| 1 Year Change | 278.62% |
| 3 Year Change | 32.93% |
| 5 Year Change | 22.82% |
| Change since IPO | -51.20% |
Recent News & Updates
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
Nov 07
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Nov 05Recent updates
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
Nov 07Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Nov 05ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company
Jul 25Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable
Jun 15Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump
Jun 05Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?
Apr 05Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet
Feb 28ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price
Jan 29Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues
Jun 08We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely
Mar 31ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé
Oct 11ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale
Oct 03ChromaDex in pact to introduce anti-aging compound in Brazil
Sep 01Ayana Bio appoints Frank Jaksch as CEO
Aug 24ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent
Aug 15Shareholder Returns
| CDXC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -10.3% | -3.7% | -3.5% |
| 1Y | 278.6% | -6.6% | 22.1% |
Return vs Industry: CDXC exceeded the US Life Sciences industry which returned -6.6% over the past year.
Return vs Market: CDXC exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| CDXC volatility | |
|---|---|
| CDXC Average Weekly Movement | 21.0% |
| Life Sciences Industry Average Movement | 9.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CDXC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CDXC's weekly volatility has increased from 15% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 106 | Rob Fried | www.chromadex.com |
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex Corporation Fundamentals Summary
| CDXC fundamental statistics | |
|---|---|
| Market cap | US$414.14m |
| Earnings (TTM) | US$1.49m |
| Revenue (TTM) | US$91.67m |
283.0x
P/E Ratio4.6x
P/S RatioIs CDXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXC income statement (TTM) | |
|---|---|
| Revenue | US$91.67m |
| Cost of Revenue | US$35.34m |
| Gross Profit | US$56.33m |
| Other Expenses | US$54.84m |
| Earnings | US$1.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.019 |
| Gross Margin | 61.45% |
| Net Profit Margin | 1.62% |
| Debt/Equity Ratio | 0% |
How did CDXC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:48 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ChromaDex Corporation is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Robert Wasserman | Dawson James Securities |